mTOR Inhibitors in Advanced Biliary Tract Cancers

Patients with advanced biliary tract cancers (BTCs), including cholangiocarcinoma (CCA), have poor prognosis so novel treatment is warranted for advanced BTC. In current review, we discuss the limitations of current treatment in BTC, the importance of mTOR signalling in BTC, and the possible role of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chao-En, Chen, Ming-Huang, Yeh, Chun-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386826/
https://www.ncbi.nlm.nih.gov/pubmed/30682771
http://dx.doi.org/10.3390/ijms20030500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386826/
https://www.ncbi.nlm.nih.gov/pubmed/30682771
http://dx.doi.org/10.3390/ijms20030500

Ejemplares similares